OBJECTIVE: Antigen-specific therapy targeting selective inhibition of autoreactive responses holds promise for controlling multiple sclerosis (MS) without disturbing homeostasis of the whole immune system. Key autoantigens in MS include myelin proteins, such as myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG). In this study, we examined the effect of transdermal therapy with myelin peptides on immune responses in the skin, lymph nodes, and peripheral blood immune cells of MS patients. METHODS: In a 1-year placebo-controlled study, 30 patients with relapsing-remitting MS were treated transdermally with a mixture of 3 myelin peptides: MBP85-99, PLP139-151, and MOG35-55, or placebo. The phenotype of immune cells in the skin was assessed using immunohistochemistry. Cell populations in lymph nodes were analyzed using flow cytometry. In peripheral blood immune cells, cytokine production was measured by enzyme-linked immunosorbent assay, and myelin-specific proliferation was examined by carboxyfluorescein succinimidyl ester-based assay. RESULTS: We found that myelin peptides applied transdermally to MS patients activated dendritic Langerhans cells in the skin at the site of immunization and induced a unique population of granular dendritic cells in local lymph nodes. In the periphery, transdermal immunization with myelin peptides resulted in the generation of type 1, interleukin-10-producing regulatory T cells, suppression of specific autoreactive proliferative responses, and suppression of interferon-γ and transforming growth factor-β production. INTERPRETATION: We demonstrate for the first time the immunoregulatory potential of transdermal immunization with myelin peptides in MS patients.
RCT Entities:
OBJECTIVE: Antigen-specific therapy targeting selective inhibition of autoreactive responses holds promise for controlling multiple sclerosis (MS) without disturbing homeostasis of the whole immune system. Key autoantigens in MS include myelin proteins, such as myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG). In this study, we examined the effect of transdermal therapy with myelin peptides on immune responses in the skin, lymph nodes, and peripheral blood immune cells of MSpatients. METHODS: In a 1-year placebo-controlled study, 30 patients with relapsing-remitting MS were treated transdermally with a mixture of 3 myelin peptides: MBP85-99, PLP139-151, and MOG35-55, or placebo. The phenotype of immune cells in the skin was assessed using immunohistochemistry. Cell populations in lymph nodes were analyzed using flow cytometry. In peripheral blood immune cells, cytokine production was measured by enzyme-linked immunosorbent assay, and myelin-specific proliferation was examined by carboxyfluorescein succinimidyl ester-based assay. RESULTS: We found that myelin peptides applied transdermally to MSpatients activated dendritic Langerhans cells in the skin at the site of immunization and induced a unique population of granular dendritic cells in local lymph nodes. In the periphery, transdermal immunization with myelin peptides resulted in the generation of type 1, interleukin-10-producing regulatory T cells, suppression of specific autoreactive proliferative responses, and suppression of interferon-γ and transforming growth factor-β production. INTERPRETATION: We demonstrate for the first time the immunoregulatory potential of transdermal immunization with myelin peptides in MSpatients.
Authors: Ada Yeste; Meghan Nadeau; Evan J Burns; Howard L Weiner; Francisco J Quintana Journal: Proc Natl Acad Sci U S A Date: 2012-06-27 Impact factor: 11.205
Authors: Duncheng Wang; Debjani Ghosh; S M Touhidul Islam; Cody D Moorman; Ashton E Thomason; Daniel S Wilkinson; Mark D Mannie Journal: J Immunol Date: 2016-09-12 Impact factor: 5.422
Authors: Jessica E Kenison; Aditi Jhaveri; Zhaorong Li; Nikita Khadse; Emily Tjon; Sara Tezza; Dominika Nowakowska; Agustin Plasencia; Vincent P Stanton; David H Sherr; Francisco J Quintana Journal: Proc Natl Acad Sci U S A Date: 2020-11-25 Impact factor: 11.205
Authors: Andreas Lutterotti; Sara Yousef; Andreas Sputtek; Klarissa H Stürner; Jan-Patrick Stellmann; Petra Breiden; Stefanie Reinhardt; Christian Schulze; Maxim Bester; Christoph Heesen; Sven Schippling; Stephen D Miller; Mireia Sospedra; Roland Martin Journal: Sci Transl Med Date: 2013-06-05 Impact factor: 17.956
Authors: Krzysztof Bryniarski; Wlodzimierz Ptak; Asha Jayakumar; Kerstin Püllmann; Michael J Caplan; Arthit Chairoungdua; Jun Lu; Brian D Adams; Emilia Sikora; Katarzyna Nazimek; Susanna Marquez; Steven H Kleinstein; Panjamaporn Sangwung; Yasuko Iwakiri; Eric Delgato; Frank Redegeld; Bart R Blokhuis; Jacek Wojcikowski; Anna Wladyslawa Daniel; Tom Groot Kormelink; Philip W Askenase Journal: J Allergy Clin Immunol Date: 2013-05-31 Impact factor: 10.793